Selecta Biosciences Inc.
Developing vaccines based on polymer nanoparticles
This article was originally published in Start Up
The technology platform that Selecta Biosciences Inc. hopes will create new vaccines combines biodegradable polymers, formulated as nanoparticles, that can be processed in such a way that they “self-assemble” along with antigens and synthetic elements into complexes able to evoke clinically relevant immune responses. Selecta says its nanoparticles stimulate a human immune response similar to that roused by naturally occurring pathogens, perhaps because they are similar in size to a virus and because antigen is arrayed on the outside to optimally interact with the body’s B cells. On the inside, the nanoparticles contain what Selecta considers a “proprietary and universal” T-cell antigen intended to elicit a strong memory T-cell response. The interior of the company’s nanoparticles also contain a TLR, or Toll-like receptor, agonist meant to act as an adjuvant.
You may also be interested in...
Vaccine and immunotherapy-focused Selecta, up to now focused on grants for funding, signs its first big pharma partner around targeted, antigen-specific programs for undisclosed allergies.
The vaccine industry has had its ups and downs the last two decades, as public opinion and investor perception has influenced both the use and production of these preventative medicines. It’s traditionally been a difficult space for smaller companies due to the financial hurdles, but a handful of start-ups, including TremRx, Selecta Biosciences Inc., Genocea Biosciences Inc. and Imaxio SA, all profiled in this issue, are banking on progress in delivery and development technology to help them raise financing for their vaccines programs.
Now on the ground in Silicon Valley, Russian sovereign fund Rusnano is investing broadly in nanotechnology around the globe, and a lot of those rubles are flowing to US biotech firms, with one major stipulation: help bring innovation and jobs back to Mother Russia.